ACK
NVS icon

Andrew C. Karlinski’s Novartis NVS Stock Holding History

Andrew C. Karlinski’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-45
Closed -$4K – 334
2022
Q2 		$4K Buy
45
+1
+2% +$88 0.01% 220
2022
Q1 		$4K Sell
44
-2
-4% -$173 0.01% 224
2021
Q4 		$4K Buy
+46
New +$3.82K 0.01% 161

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Andrew C. Karlinski's NVS Position: Q3 2022 in Review

Andrew C. Karlinski sold out of Novartis (NVS) in Q3 2022, closing a stake of 45 shares — an estimated $4K sold.

Andrew C. Karlinski first reported a position in NVS in Q4 2021 and held it in 3 quarters. The position peaked at $4K in Q2 2022. 1,088 funds tracked by Wall St. Rank hold NVS as of Q3 2022.

  • Andrew C. Karlinski reported no remaining Novartis position as of Q3 2022 after selling out during the quarter.
  • Andrew C. Karlinski sold 45 Novartis shares in Q3 2022, an estimated $4K.
  • Andrew C. Karlinski first reported a position in Novartis in Q4 2021 and held it in 3 quarters.
  • Andrew C. Karlinski's Novartis position peaked at $4K in Q2 2022.
  • 1,088 funds tracked by Wall St. Rank held Novartis as of Q3 2022.

Based on Andrew C. Karlinski's 13F filing for Q3 2022, filed 14 Nov 2022.